Skip to NavigationSkip to content

type 2 diabetes

New data from diabetes prevention programme shows a reduction of type 2 diabetes

The Diabetes Prevention Program Outcomes Study (DPPOS) of 2,000 people showed a significant reduction in the participants’ risk of developing type 2 diabetes when they pursued weight loss programs or metformin treatment.

Fast-acting mealtime insulin approved for children with diabetes in Canada

Photo by Alan Levine

Health Canada has approved Novo Nordik’s Fiasp, a faster acting mealtime insulin, for children aged 2 and above with type 1 or type 2 diabetes.

The regulatory body also approved Fiasp to include use in insulin infusion pumps for the improvement of glycemic control.

Dave Prowten, President and CEO of JDRF Canada, said on the approval: “We welcome the paediatric approval of Fiasp for younger Canadians, providing greater choice for effective disease management to support easier, healthier and safer lives for young people with type 1 diabetes.”

The March 2020 issue of Pharmafocus is available to read free online now!

The latest monthly edition of Pharmafocus, the March issue, is available to read for free online now!

The coronavirus continues to spread and test the response strategies of nations around the world, and pharma and biotech companies are scrambling to develop interventions for the virus. Gilead is currently ahead in the race, with its therapy remdesivir thought to be potentially ready for approval in China as early as May this year. You can read the full story so far in our front page story.

Insulin pumps tied to over 2,000 injuries recalled

Over 300,000 insulin pumps have been recalled by Medtronic after injuries and one death were reported due to devices malfunctioning.

The company received 26,421 complaints regarding the malfunctions, which caused 2,175 injuries. The FDA said this is a Class I recall which is the most serious type of recall.

Type 2 diabetes drug Rosiglitazone increases risk of heart problems

A new study has given further evidence that rosiglitazone can contribute to risk of heart problems and heart failure.

The British Medical Journal study was led by the Yale School of Public Health. It analysed the results of more than 130 trials involving over 48,000 adult patients that compared rosiglitazone with any control for at least 24 weeks. Individual Patient Data (IPD) was available for 33 trials, included 21156 patients. The remaining trials only had summary level data available.

New report finds that health inequality in the UK greater than previously thought

Men are living seven years in poor health while women are living nearly ten years, according to a new report.

The research titled ‘The Health of the Nation: A Strategy for Healthier Longer Lives’, has been written by the All-Party Parliamentary Group (APPG) for longevity based on new NHS data.

It found that men on average were being diagnosed with their first long-term medical condition at 56 and women at 55. In poor areas, women were diagnosed at 47 with men at 49 years old.

Type 2 diabetes cases up 40% in Scotland

According to a new study, Scotland’s cases of type 2 diabetes has increased by 40% over the last 10 years.

Diabetes Scotland's figures show cases rose from 190,772 to 267,615 between 2008 and 2018. They also estimate that 26,347 people are living with the condition.

Diabetes Scotland said the figures prove this is now an urgent public health crisis. Angela Mitchel, the Director of the organization, said: “Solving the crisis depends on decisive action led by both the UK and Scottish governments, supported by industry and delivered across our society.

Novo Nordisk to offer US patient’s in immediate need free insulin

Novo Nordisk said it would offer free, one-time supply of insulin to those in need, amidst rising insulin prices.

Novo has said that patients with a prescription can get the free insulin, in a supply of up to three vials or two packs of pens of its insulin. But after this they have to find a longer-term solution.

This follows a move back in September where they allowed their US patients to buy three vials, or two packs of pens, of its analogue insulins for $99.

FDA approves artificial pancreas developed by the University of Virginia

The FDA has approved an artificial pancreas system based on technology from the University of Virginia's Center for Diabetes Technology.

The University says that the artificial pancreas system, called Control-IQ and manufactured by Tandem Diabetes Care, tracks blood glucose levels with a continuous glucose monitor (Dexcom G6 CGM) and automatically delivers the hormone insulin as needed.

Using this, means that pateints do not have to test their blood sugar levels multiple times a day by fingerstick, or deliver insulin by multiple daily injections.

AstraZeneca's Qtrilment scores European authorisation in type 2 diabetes

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to improve glycaemic control in adults with type-2 diabetes (T2D).

Specifically, the approval covers T2D patients who have not experienced adequate glycaemic control with metformin with or without sulphonylurea and in combination with either Onglyza or Forxiga, or in patients who are already receiving treatment with metformin, Onglyza and Forxiga.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches